Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04634916 · ClinicalTrials.gov registry record · NA

Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

A NA study of End Stage Renal Disease and Arteriovenous Fistula, sponsored by C. R. Bard.

Recruiting
Registry status
NA
Development phase
280
Enrollment target
17
Study locations

NCT04634916: Recruiting NA study of End Stage Renal Disease and Arteriovenous Fistula, sponsored by C. R. Bard.

NCT04634916 is a NA study of End Stage Renal Disease and Arteriovenous Fistula that is actively recruiting participants, run by C. R. Bard. The registered enrollment target is 280 participants, below the 830-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (66% lower). The trial reports 17 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04634916, a NA study of End Stage Renal Disease and Arteriovenous Fistula, is actively recruiting participants, sponsored by C. R. Bard.

RECRUITING
Registry status
NA
Development phase
280 participants
Enrollment target
17
Study locations

Study Summary

A prospective, single-arm, multi-center post-market surveillance study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis.

Primary Outcome

The percentage of subjects dialyzed using successful 2-needle access of the endoAVF for at least 75% of dialysis sessions over a continuous 28-day period

Interventions

  • DEVICE EndoAVF Creation

Study Locations (17)

Florida

  • First Coast Cardiovascular Institute Pa - Jacksonville
  • Radiology and Imaging Specialists - Lakeland
  • Vascular and Spine Institute Inc - Miami

Massachusetts

  • Kidney Care and Transplant Services of NE - Springfield
  • Kidney Care & Transplant Services of New England - West Springfield
  • UMass Chan School of Medicine - Worcester

California

  • California Institute of Renal Research - La Jolla
  • San Francisco Vein & Vascular - San Francisco

Tennessee

  • Vascular Institute of Chattanooga - Chattanooga
  • Bluff City Vascular - Memphis

Texas

  • University of Texas Southwestern Medical Center - Dallas
  • Houston Methodist - Houston

New York

  • Albany Medical Center - Albany

North Carolina

  • NC Nephrology - Raleigh

Ohio

  • ProMedica Toledo Hospital - Toledo

Trial Details

FieldValue
Enrollment Target 280 participants
Start Date 2021-03-26
Est. Completion 2027-09
Phase NA
C. R. Bard

75 total trials

What NCT04634916 shows while recruiting

NCT04634916 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, below the 830-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (66% lower).

The record links to 3 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which EndoAVF Creation is the first listed.

NCT04634916 lists 17 locations in 10 states (Florida, Massachusetts, California).

Frequently Asked Questions

What is clinical trial NCT04634916 about?

NCT04634916 is a clinical study titled "Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System". A prospective, single-arm, multi-center post-market surveillance study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis.

What is the current status of trial NCT04634916?

This trial is currently recruiting. It is a NA study. The enrollment target is 280 participants. The study started on 2021-03-26. Estimated completion is 2027-09.

What conditions does trial NCT04634916 study?

This clinical trial studies the following conditions: End Stage Renal Disease, Arteriovenous Fistula, Kidney Disease, End-Stage.

What interventions are being tested in trial NCT04634916?

The interventions under investigation include: EndoAVF Creation (DEVICE).

Who is sponsoring clinical trial NCT04634916?

This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04634916 being conducted?

This trial has 17 study locations across California, Florida, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for End Stage Renal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04634916's enrollment target sits among peer trials

280 18th of 86 higher than 68 of 86 other End Stage Renal Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04084730 · 280 participants · Phase 2

    Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer

  • NCT04518657 · 280 participants · NA

    Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis

  • NCT04829617 · 280 participants · NA

    Promoting Well-being and Health in Heart Failure

  • NCT05142189 · 280 participants · Phase 1

    Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04634916, the US trial registry maintained by the National Library of Medicine. NCT04634916 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.